Discouraging OS Results With Bevacizumab in Ovarian Cancer
Long-term follow-up of a phase III trial showed overall survival results for bevacizumab plus chemotherapy in women with ovarian, fallopian tube, or primary peritoneal cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 26, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Peritoneal Carcinomatosis Profiles Highlight Gastric Cancer Targets Peritoneal Carcinomatosis Profiles Highlight Gastric Cancer Targets
Sequencing of whole exome and transcriptome of peritoneal carcinomatosis (PC) in patients with gastric adenocarcinoma (GAC) has given novel insights and opened up new therapeutic opportunities, according to Texas-based researchers.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 22, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Novel Imaging May Make Peritoneal Mesothelioma Surgery More Effective
Dr. James Cusack at Massachusetts General Hospital has begun using a novel imaging system for patients with peritoneal mesothelioma that could better identify tumor cells during surgery, reducing the chance of recurrence.
Cusack, an associate professor of surgery at the Harvard University Medical School, is also studying the molecular imaging technology with select cases of appendiceal, ovarian and gastrointestinal cancers.
The single-center clinical trial, which started April 3, aims to determine safety and efficacy of the procedure for peritoneum metastases, according to Cusack.
The Lumicell System already has been studi...
Source: Asbestos and Mesothelioma News - May 6, 2019 Category: Environmental Health Authors: Daniel King Source Type: news
Smart nanoparticles help improve treatment of peritoneal tumors
(Estonian Research Council) Research carried out at the University of Tartu Faculty of Medicine used nanoparticles for the development of new imaging and treatment methods for peritoneal cancers. Tests showed that precision-guided anticancer nanoparticles have improved efficacy and reduced side effects. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 22, 2019 Category: International Medicine & Public Health Source Type: news
Lab-grown mini tumors could help identify personalized treatments for people with rare cancers
UCLA scientists have developed a new method to quickly screen hundreds of drugs in order to identify treatments that can target specific tumors.The approach could help scientists understand how a person ’s tumor would respond to a certain drug or drug combination, and it could help guide treatment decisions for people with rare and hard-to-treat cancers. Apaper detailing the new technique was published in Communications Biology.“We always focus on how we need new and better drugs to treat cancer,” said Alice Soragni, the senior author of the study and a scientist at the UCLA Jonsson Comprehensive Cancer Center. “W...
Source: UCLA Newsroom: Health Sciences - February 25, 2019 Category: Universities & Medical Training Source Type: news
New recommendations say not all women need genetic testing for cancer. Critics say it could cost lives
Primary care providers should screen women for personal, family and/or ethnic history of breast, ovarian, tubal or peritoneal cancer to decide who should undergo genetic counseling for BRCA1 and BRCA2 mutations, the US Preventive Services Task Force recommended Tuesday. The mutations increase a woman's cancer risk. (Source: CNN.com - Health)
Source: CNN.com - Health - February 19, 2019 Category: Consumer Health News Source Type: news
Cytoreductive Surgery/HIPEC: Safer for Peritoneal Metastases? (CME/CE)
(MedPage Today) -- Study shows lower infection, 30-day mortality vs other high-risk procedures, but experts question validity of comparisons (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - January 18, 2019 Category: Surgery Source Type: news
Living With Cancer: Ovarian cancer risk after hysterectomy
Ovarian cancer risk after hysterectomy? If you've had a hysterectomy, your risk of developing ovarian cancer or primary peritoneal cancer,?a type of cancer that acts like ovarian cancer, depends on the type of hysterectomy you had.?Learn more from Dr. Yvonne Butler Tobah, a Mayo Clinic OB-GYN Monoclonal antibody drugs for cancer? Monoclonal antibody drugs use [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - January 11, 2019 Category: Databases & Libraries Source Type: news
Role of PARP Inhibitors in BRCA-Related Malignancies Role of PARP Inhibitors in BRCA-Related Malignancies
Review the pharmacology of PARP inhibitors and their use in BRCA-mutated malignancies including breast, ovarian, fallopian tube, and primary peritoneal cancers.U.S. Pharmacist (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 6, 2018 Category: Consumer Health News Tags: Pharmacist Journal Article Source Type: news
Ovarian Epithelial Fallopian Tube Cancer Treatment
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 26, 2018 Category: General Medicine Source Type: news
Noninferiority of Neoadjuvant Chemo Cannot Be Confirmed in Ovarian Cancer Trial
Dave LevitanJun 6, 2018The noninferiority of neoadjuvant chemotherapy vs upfront surgery could not be confirmed with regard to overall survival in patients with ovarian, tubal, and peritoneal cancers. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2018 Category: Cancer & Oncology Authors: A Source Type: news
Hot Chemo Fails in Rare Cancer
(MedPage Today) -- HIPEC and surgery equals surgery alone in peritoneal carcinomatosis (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 4, 2018 Category: Gastroenterology Source Type: news
No OS Benefit From HIPEC in Colorectal Cancer
Bryant FurlowJun 4, 2018Overall, patients with mCRC and isolated peritoneal carcinomatosis did not benefit when hyperthermic intraperitoneal chemotherapy was added to surgery. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2018 Category: Cancer & Oncology Authors: A Source Type: news
FDA Approves Rucaparib for Recurrent Ovarian Cancer Maintenance Therapy
The FDA has granted approval of rucaparib for maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: CancerNetwork)
Source: CancerNetwork - April 11, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers SiteTerms/www.cannabissciencetech.com/News Ovarian Cancer Source Type: news
Clovis Oncology ovarian cancer drug receives fast-tracked FDA approval
Clovis Oncology won the fast-tracked verdict it hoped for on Friday when the U.S. Food and Drug Administration approved marketing the company's ovarian cancer drug rucaparib to treat a broader range of patients.
The FDA approved the Boulder-based company (Nasdaq: CLVS) selling rucaparib as a maintenance treatment in women “with recurrent epithelial ovarian, fallopian tu be, or primary peritoneal cancer who are platinum sensitive” and regardless of their genetic profile.
The FDA completed its… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 6, 2018 Category: American Health Authors: Greg Avery Source Type: news
